Trial Outcomes & Findings for The Efficacy of Aerobic Exercise Training on ANS and Endothelial Function in Compensated Cirrhosis (NCT NCT06288828)

NCT ID: NCT06288828

Last Updated: 2026-05-22

Results Overview

Heart rate variability (HRV) was assessed using a 15-minute resting ECG recording. This table reports three time-domain measures: 1) SDNN (Standard deviation of all NN intervals), 2) RMSSD (Root mean square of successive differences), and 3) SDANN (Standard deviation of the average NN intervals). These parameters reflect autonomic nervous system activity and cardiac vagal tone. All data are reported in milliseconds. Higher values indicate better autonomic regulation. Only these three time-domain parameters are presented in this table.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

Change from Baseline (week 0) at Week 16

Results posted on

2026-05-22

Participant Flow

Participants were recruited from patients attending the Liver Unit of the Division of Gastroenterology, Department of Medicine, at King Chulalongkorn Memorial Hospital. The recruitment period spanned from March 12, 2024, to June 30, 2025.

A total of 525 patients who visited the Liver Unit, Division of Gastroenterology, at King Chulalongkorn Memorial Hospital were screened for eligibility. Potential participants were evaluated based on the inclusion and exclusion criteria. Of those screened, 475 patients were excluded prior to randomization: 303 did not meet the specific study criteria, and 172 declined to participate in the study for personal reasons or lack of interest in the intervention

Participant milestones

Participant milestones
Measure
Aerobic Exercise Group (AE)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation). The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions. Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Control Group (CG)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia). Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided. To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Overall Study
STARTED
25
25
Overall Study
COMPLETED
23
21
Overall Study
NOT COMPLETED
2
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Aerobic Exercise Group (AE)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation). The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions. Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Control Group (CG)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia). Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided. To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Overall Study
Lost to Follow-up
1
3
Overall Study
intercurrent event
1
1

Baseline Characteristics

Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Aerobic Exercise Group (AE)
n=25 Participants
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation). The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions. Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Control Group (CG)
n=25 Participants
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia). Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided. To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
Total
n=50 Participants
Total of all reporting groups
Age, Continuous
62.00 years
STANDARD_DEVIATION 7.61 • n=2 Participants
63.16 years
STANDARD_DEVIATION 6.37 • n=4 Participants
62.58 years
STANDARD_DEVIATION 6.97 • n=6 Participants
Sex: Female, Male
Female
19 Participants
n=2 Participants
11 Participants
n=4 Participants
30 Participants
n=6 Participants
Sex: Female, Male
Male
6 Participants
n=2 Participants
14 Participants
n=4 Participants
20 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
n=2 Participants
25 Participants
n=4 Participants
50 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Child-Pugh score
score 5
22 Participants
n=2 Participants
25 Participants
n=4 Participants
47 Participants
n=6 Participants
Child-Pugh score
score 6
3 Participants
n=2 Participants
0 Participants
n=4 Participants
3 Participants
n=6 Participants
Etiologies of cirrhosis
Hepatitis B
6 Participants
n=2 Participants
17 Participants
n=4 Participants
23 Participants
n=6 Participants
Etiologies of cirrhosis
Hepatitis C
10 Participants
n=2 Participants
7 Participants
n=4 Participants
17 Participants
n=6 Participants
Etiologies of cirrhosis
Non-alcoholic steatohepatitis (NASH)
9 Participants
n=2 Participants
6 Participants
n=4 Participants
15 Participants
n=6 Participants
Etiologies of cirrhosis
Autoimmune hepatitis
3 Participants
n=2 Participants
1 Participants
n=4 Participants
4 Participants
n=6 Participants
Etiologies of cirrhosis
Alcoholic cirrhosis
1 Participants
n=2 Participants
1 Participants
n=4 Participants
2 Participants
n=6 Participants
Etiologies of cirrhosis
others
0 Participants
n=2 Participants
1 Participants
n=4 Participants
1 Participants
n=6 Participants
Autonomic function test : Ewing autonomic battery test
No dysfunction
8 Participants
n=2 Participants
6 Participants
n=4 Participants
14 Participants
n=6 Participants
Autonomic function test : Ewing autonomic battery test
Mild dysfunction
7 Participants
n=2 Participants
9 Participants
n=4 Participants
16 Participants
n=6 Participants
Autonomic function test : Ewing autonomic battery test
Moderate dysfunction
7 Participants
n=2 Participants
4 Participants
n=4 Participants
11 Participants
n=6 Participants
Autonomic function test : Ewing autonomic battery test
Severe dysfunction
3 Participants
n=2 Participants
6 Participants
n=4 Participants
9 Participants
n=6 Participants
Appendicular mass/height^2 from DXA
6.13 kg/m^2
STANDARD_DEVIATION 1.02 • n=2 Participants
6.51 kg/m^2
STANDARD_DEVIATION 0.94 • n=4 Participants
6.32 kg/m^2
STANDARD_DEVIATION 0.98 • n=6 Participants
Total Fat Mass from DXA
39.10 kilograms
STANDARD_DEVIATION 8.39 • n=2 Participants
36.69 kilograms
STANDARD_DEVIATION 8.89 • n=4 Participants
37.90 kilograms
STANDARD_DEVIATION 8.64 • n=6 Participants
Body composion
Skeletal muscle mass from BIA
22.65 Kilograms
STANDARD_DEVIATION 4.99 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
25.48 Kilograms
STANDARD_DEVIATION 5.17 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
24.07 Kilograms
STANDARD_DEVIATION 5.08 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
Body composion
Fat Mass from BIA
21.72 Kilograms
STANDARD_DEVIATION 8.50 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
23.91 Kilograms
STANDARD_DEVIATION 8.94 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
22.82 Kilograms
STANDARD_DEVIATION 8.72 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
Body composion
Total Fat Mass from DXA
35.81 Kilograms
STANDARD_DEVIATION 7.56 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
41.16 Kilograms
STANDARD_DEVIATION 7.56 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
38.49 Kilograms
STANDARD_DEVIATION 7.56 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
6-Minute Walk test (6MWT)
377.84 meters
STANDARD_DEVIATION 68.76 • n=2 Participants
391.39 meters
STANDARD_DEVIATION 91.64 • n=4 Participants
384.62 meters
STANDARD_DEVIATION 81.01 • n=6 Participants
Handgrip strength
26.35 kilograms
STANDARD_DEVIATION 7.85 • n=2 Participants
31.37 kilograms
STANDARD_DEVIATION 8.69 • n=4 Participants
28.86 kilograms
STANDARD_DEVIATION 8.28 • n=6 Participants
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
AST
42.60 U/L
STANDARD_DEVIATION 17.66 • n=2 Participants
32.40 U/L
STANDARD_DEVIATION 8.86 • n=4 Participants
37.50 U/L
STANDARD_DEVIATION 13.97 • n=6 Participants
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
ALT
36.08 U/L
STANDARD_DEVIATION 18.25 • n=2 Participants
26.96 U/L
STANDARD_DEVIATION 11.78 • n=4 Participants
31.52 U/L
STANDARD_DEVIATION 15.02 • n=6 Participants
Serum ammonia
43.52 µmol/L
STANDARD_DEVIATION 11.99 • n=2 Participants
50.18 µmol/L
STANDARD_DEVIATION 26.83 • n=4 Participants
46.85 µmol/L
STANDARD_DEVIATION 20.78 • n=6 Participants
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
SDNN
82.18 milliseconds
n=2 Participants
67.05 milliseconds
n=4 Participants
75.87 milliseconds
n=6 Participants
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
SDANN
62.73 milliseconds
n=2 Participants
58.91 milliseconds
n=4 Participants
62.73 milliseconds
n=6 Participants
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
RMSSD
65.46 milliseconds
n=2 Participants
51.74 milliseconds
n=4 Participants
62.70 milliseconds
n=6 Participants
pNN50
11.51 %
n=2 Participants
3.37 %
n=4 Participants
9.42 %
n=6 Participants
Heart Rate Variability (HRV): Frequency Domain Measures
Total power (TP)
5972.44 ms^2
n=2 Participants
4259.97 ms^2
n=4 Participants
4449.37 ms^2
n=6 Participants
Heart Rate Variability (HRV): Frequency Domain Measures
High Frequency (HF) Power
1445.00 ms^2
n=2 Participants
680.14 ms^2
n=4 Participants
1024.34 ms^2
n=6 Participants
Heart Rate Variability (HRV): Frequency Domain Measures
Low Frequency (LF) Power
1074.85 ms^2
n=2 Participants
1018.52 ms^2
n=4 Participants
1074.85 ms^2
n=6 Participants
Heart Rate Variability (HRV): Frequency Domain Measures
Very Low Frequency (VLF) Power
1333.62 ms^2
n=2 Participants
1437.87 ms^2
n=4 Participants
1340.61 ms^2
n=6 Participants
LF/HF Ratio (Low Frequency/High Frequency Ratio)
0.46 Ratio
n=2 Participants
0.93 Ratio
n=4 Participants
0.58 Ratio
n=6 Participants
Flow-mediated Dilation (FMD)
5.62 Percent
STANDARD_DEVIATION 3.62 • n=2 Participants
6.80 Percent
STANDARD_DEVIATION 3.92 • n=4 Participants
6.21 Percent
STANDARD_DEVIATION 3.77 • n=6 Participants
Splanchnic Vascular Velocity
Superior Mesenteric Artery: PSV
169.91 centimeters per second (cm/s)
STANDARD_DEVIATION 40.70 • n=2 Participants
178.18 centimeters per second (cm/s)
STANDARD_DEVIATION 40.17 • n=4 Participants
174.05 centimeters per second (cm/s)
STANDARD_DEVIATION 40.24 • n=6 Participants
Splanchnic Vascular Velocity
Superior Mesenteric Artery: EDV
21.98 centimeters per second (cm/s)
STANDARD_DEVIATION 11.63 • n=2 Participants
27.84 centimeters per second (cm/s)
STANDARD_DEVIATION 12.49 • n=4 Participants
24.91 centimeters per second (cm/s)
STANDARD_DEVIATION 12.33 • n=6 Participants
Splanchnic Vascular Velocity
Superior Mesenteric Artery: TAMAX
59.97 centimeters per second (cm/s)
STANDARD_DEVIATION 18.34 • n=2 Participants
65.38 centimeters per second (cm/s)
STANDARD_DEVIATION 19.32 • n=4 Participants
62.68 centimeters per second (cm/s)
STANDARD_DEVIATION 18.83 • n=6 Participants
Splanchnic Vascular Velocity
Celiac Artery: PSV
172.29 centimeters per second (cm/s)
STANDARD_DEVIATION 60.81 • n=2 Participants
184.19 centimeters per second (cm/s)
STANDARD_DEVIATION 53.81 • n=4 Participants
178.24 centimeters per second (cm/s)
STANDARD_DEVIATION 57.19 • n=6 Participants
Splanchnic Vascular Velocity
Celiac Artery: EDV
43.20 centimeters per second (cm/s)
STANDARD_DEVIATION 14.95 • n=2 Participants
41.29 centimeters per second (cm/s)
STANDARD_DEVIATION 17.14 • n=4 Participants
42.25 centimeters per second (cm/s)
STANDARD_DEVIATION 15.96 • n=6 Participants
Splanchnic Vascular Velocity
Celiac Artery: TAMAX
87.60 centimeters per second (cm/s)
STANDARD_DEVIATION 30.53 • n=2 Participants
86.01 centimeters per second (cm/s)
STANDARD_DEVIATION 25.44 • n=4 Participants
86.81 centimeters per second (cm/s)
STANDARD_DEVIATION 27.84 • n=6 Participants
Splanchnic Blood Flow Volume
Superior Mesenteric Artery Volume Flow
626.62 ml/min
STANDARD_DEVIATION 286.01 • n=2 Participants
737.36 ml/min
STANDARD_DEVIATION 378.03 • n=4 Participants
681.99 ml/min
STANDARD_DEVIATION 337.28 • n=6 Participants
Splanchnic Blood Flow Volume
Celiac Artery Volume Flow
859.18 ml/min
STANDARD_DEVIATION 478.67 • n=2 Participants
963.94 ml/min
STANDARD_DEVIATION 466.00 • n=4 Participants
911.56 ml/min
STANDARD_DEVIATION 470.18 • n=6 Participants
Splanchnic Blood Flow Volume
Portal Vein Volume Flow
1661.75 ml/min
STANDARD_DEVIATION 817.59 • n=2 Participants
1812.50 ml/min
STANDARD_DEVIATION 973.27 • n=4 Participants
1737.13 ml/min
STANDARD_DEVIATION 891.75 • n=6 Participants
Serum Albumin
4.38 g/dL
STANDARD_DEVIATION 0.29 • n=2 Participants
4.23 g/dL
STANDARD_DEVIATION 0.48 • n=4 Participants
4.31 g/dL
STANDARD_DEVIATION 0.40 • n=6 Participants

PRIMARY outcome

Timeframe: Change from Baseline (week 0) at Week 16

Population: All participants who underwent randomization were included in the final analysis according to the modified Intention-to-Treat (ITT) principle.

Heart rate variability (HRV) was assessed using a 15-minute resting ECG recording. This table reports three time-domain measures: 1) SDNN (Standard deviation of all NN intervals), 2) RMSSD (Root mean square of successive differences), and 3) SDANN (Standard deviation of the average NN intervals). These parameters reflect autonomic nervous system activity and cardiac vagal tone. All data are reported in milliseconds. Higher values indicate better autonomic regulation. Only these three time-domain parameters are presented in this table.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
SDNN
75.87 milliseconds
Interval 32.55 to 117.31
55.13 milliseconds
Interval 42.14 to 137.86
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
SDANN
-4.77 milliseconds
Interval -11.57 to 28.31
-14.91 milliseconds
Interval -60.63 to 19.36
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
RMSSD
-5.08 milliseconds
Interval -24.46 to 28.29
-28.61 milliseconds
Interval -60.59 to 5.66

PRIMARY outcome

Timeframe: Change from Baseline (week 0) at week 16

A time-domain measure of heart rate variability (HRV) reflecting parasympathetic activity. It is calculated as the percentage of successive normal-to-normal (NN) intervals that differ by more than 50 milliseconds. Data were collected using 3-lead ECG during a 15-minute resting period."

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Time Domain Outcome: pNN50
0 percentage of successive NN intervals
Interval -15.55 to 4.76
0.86 percentage of successive NN intervals
Interval -7.71 to 3.69

PRIMARY outcome

Timeframe: Change from Baseline (week 0) at Week 16

Assessment of frequency-domain components of heart rate variability, including Total Power (TF), High Frequency (HF), Low Frequency (LF), and Very Low Frequency (VLF). Analysis was performed using Adinstrument (tm) on a 15-minute ECG recording at rest. These parameters reflect the power distribution across different frequency bands and represent autonomic nervous system activity. Data presented in the table represent the change from baseline to Week 16.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
HRV Frequency Domain Measures: TP, HF, LF, VLF
High Frequency (HF)
-49.04 ms^2
Interval -714.52 to 1048.74
-174.58 ms^2
Interval -3864.3 to 78.04
HRV Frequency Domain Measures: TP, HF, LF, VLF
Total Frequency Power (TP)
-627.24 ms^2
Interval -8393.35 to 861.68
-626.90 ms^2
Interval -9040.66 to 4.87
HRV Frequency Domain Measures: TP, HF, LF, VLF
Low Frequency (LF)
-188.32 ms^2
Interval -2127.56 to 335.0
-392.99 ms^2
Interval -2991.63 to 160.24
HRV Frequency Domain Measures: TP, HF, LF, VLF
Very Low Frequency (VLF)
-436.11 ms^2
Interval -4111.51 to 343.63
-498.32 ms^2
Interval -912.69 to 531.54

PRIMARY outcome

Timeframe: Change from Baseline (week 0) and Week 16

Categorical assessment of changes in autonomic function using the Ewing Autonomic Battery test. Participants are classified into three categories: 'Improved', 'No change', or 'Worsened' based on their composite score changes from baseline to Week 16. Results are reported as the number of participants in each category.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
Improved
7 Participants
10 Participants
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
No change
11 Participants
9 Participants
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
Worsened
5 Participants
2 Participants

PRIMARY outcome

Timeframe: Change from Baseline (week 0) at Week 16

Assessment of the change in brachial artery flow-mediated dilation (FMD) from baseline to Week 16. FMD was determined by ultrasound as the percentage increase in arterial diameter during reactive hyperemia compared to baseline diameter. Results are reported as the percentage change (%). Positive values indicate an improvement in endothelial-dependent vasodilation.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Endothelial Function Test: Change in Flow-mediated Dilation (FMD)
-1.17 % of FMD response
Standard Deviation 4.99
0.28 % of FMD response
Standard Deviation 3.99

PRIMARY outcome

Timeframe: Change from baseline (week 0) to week 16

The LF/HF ratio is calculated as the ratio between the absolute power of the Low Frequency (LF) and High Frequency (HF) bands. It is used as an index of sympathovagal balance. Results are reported as a ratio (unitless).

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
HRV Frequency Domain Measures: Low Frequency/High Frequency (LF/HF) Ratio
0.52 Ratio
Interval 0.42 to 2.09
0.53 Ratio
Interval 0.41 to 1.08

SECONDARY outcome

Timeframe: Change from Baseline (week 0) at week 16

Lean appendicular mass (kg) from Dual energy X-ray absorptiometry (DXA)

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Muscle Mass Change
0.33 kg
Standard Deviation 1.62
-1.45 kg
Standard Deviation 0.9

SECONDARY outcome

Timeframe: Change from Baseline (week 0) at week 16

6-minute walk test (minute)

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Physical Function
24 meter
Interval 10.0 to 52.0
2 meter
Interval -23.0 to 13.0

SECONDARY outcome

Timeframe: Change from Baseline (week 0) at week 16

Handgrip strength (kg) from dynamometer

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Muscle Strength Change
-1.80 Kg
Standard Deviation 3.24
0.39 Kg
Standard Deviation 3.59

SECONDARY outcome

Timeframe: Baseline and after 16-week intervention

Blood-flow parameters derived from mesenteric Doppler ultrasound (celiac and superior mesenteric arteries, portal vein) were obtained as exploratory markers of splanchnic circulation.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=19 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Splanchnic Volume Flow
Portal vein volume flow
312.67 mL/min
Standard Deviation 690.18
218.48 mL/min
Standard Deviation 315.05
Splanchnic Volume Flow
Celiac artery volume flow
167.63 mL/min
Standard Deviation 402.11
-5.46 mL/min
Standard Deviation 32.15
Splanchnic Volume Flow
Superior mesenteric artery volume flow
39.75 mL/min
Standard Deviation 180.35
66.03 mL/min
Standard Deviation 335.57

SECONDARY outcome

Timeframe: Baseline and Week 16

Assessment of the correlation between the change in appendicular muscle mass index (measured by appendicular mass divided by height squared via Dual-Energy X-ray Absorptiometry; DXA) and the change in serum ammonia levels from baseline to week 16. Statistical significance is evaluated using Spearman's rank correlation coefficient for non-normally distributed data.

Outcome measures

Outcome measures
Measure
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
The Association Between Changes in Muscle Mass and Changes in Serum Ammonia Levels
-0.052 Correlation coefficient
-0.40 Correlation coefficient

Adverse Events

Exercise Group

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Exercise Group
n=25 participants at risk
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
Control Group
n=25 participants at risk
The control group will solely receive nutritional guidance and maintain their physical inactivity.
Musculoskeletal and connective tissue disorders
Muscle strain
4.0%
1/25 • from enrollment until end of follow-up, up to 16 week
0.00%
0/25 • from enrollment until end of follow-up, up to 16 week
Musculoskeletal and connective tissue disorders
Knee pain
20.0%
5/25 • from enrollment until end of follow-up, up to 16 week
0.00%
0/25 • from enrollment until end of follow-up, up to 16 week

Additional Information

Dr. Sirinda Kittiprachakul

Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University

Phone: +66-2-256-4000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place